Strategic partnerships Parabilis Med has a strategic R&D collaboration with Regeneron worth up to $2.3B, signaling openness to co-development and large-pharma partnerships to advance the Helicon platform and tackle undruggable targets; potential to pursue additional co-development or license-out arrangements with other pharma players.

Helicon platform The Helicon platform enables stabilized helical peptides to modulate intracellular protein-protein interactions and expand modalities to degraders and radioligands, creating multiple partnering angles for target discovery, licensing, or joint development with oncology-focused companies.

Lead program FOG-001 is a first-in-class TCF-blocking β-catenin inhibitor in Phase 1/2 for colorectal cancer and other solid tumors, offering opportunities for partnerships around manufacturing, biomarker programs, expansion into adjacent indications, or licensing of the program as a stepping stone to broader Helicon collaborations.

Financial strength Strong capital position evidenced by multi-hundred-million-dollar IPO financing, a high-profile market debut, and investor backing enabling long-term strategic collaborations, upfronts, and milestones aligned with rapid pipeline expansion.

Cambridge advantage Based in Cambridge, MA, the company benefits from a dense biotech ecosystem, access to top talent and partner networks, and proximity to potential manufacturing and regulatory partners, making it attractive for regional co-development, clinical supply, and alliance opportunities.